By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cytogen Corporation 

650 College Road East

Princeton  New Jersey  08540  U.S.A.
Phone: 609-750-8200 Fax: 609-452-2476

Cytogen Corporation is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology. Currently marketed products include ProstaScintâ (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeedä I-125 and Pd-103 (two uniquely designed next generation radioactive seed implants for the treatment of localized prostate cancer), and Quadrametâ (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by developing its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences of Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information.

Last Updated: 10-16-02

Key Statistics

Ownership: Public

Web Site: Cytogen Corporation
Employees: 70
Symbol: CYTO



Advanced Magnetics, Inc.  Marketing, licensing and supply agreement for Combidexâ and Code 7228, magnetic resonance imaging (MRI) contrast agents being developed for oncology applications

Dowpharma  License to Quadramet

DRAXIS Health, Inc.  Marketing, licensing and supply arrangement for BrachySeed iodine and palladium next-generation brachytherapy implants for the treatment of localized prostate cancer

Molecular Staging Inc.  World-wide exclusive license for Rolling Circle Amplification Technology, or RCAT, to develop in vitro diagnostic tests using both PSMA and PSA

NW Bio  Development of ex vivo prostate cancer immunotherapy

Company News
EUSA Pharma Completes Acquisition Of Cytogen Corporation (CYTO) 5/9/2008 6:54:47 AM
Cytogen Corporation (CYTO) Reports First Quarter 2008 Financial Results 5/8/2008 8:57:38 AM
Cytogen Corporation (CYTO)'s Auditors Expressed Going-Concern Qualification 3/20/2008 8:43:53 AM
Cytogen Corporation (CYTO) Reports Fourth Quarter and Full Year 2007 Financial Results 3/14/2008 9:14:22 AM
Cytogen Corporation (CYTO) Says CEO Resigns; Names Replacement 11/12/2007 6:54:36 AM
Cytogen Corporation (CYTO) Reports Third Quarter 2007 Financial Results 11/7/2007 12:46:41 PM
Cytogen Corporation (CYTO) Retains ThinkEquity Partners to Assist in the Evaluation of Potential Strategic Alternatives 11/5/2007 11:16:35 AM
Cytogen Corporation (CYTO) to Present at the Biotechnology Industry Organization (BIO) Investor Forum 2007 10/3/2007 10:56:11 AM
Outcomes Data Demonstrating Prognostic Value of Cytogen Corporation (CYTO)'s PROSTASCINT Published in Peer-Reviewed Journal Urology 9/10/2007 11:52:49 AM
Cytogen Corporation (CYTO) to Present at Upcoming Investor Conferences in September 8/28/2007 2:39:29 PM